Site menu

Search by ticker code:
Generic filters

Menu

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Pro Medicus (ASX:PME) To Showcase Visage AI Accelerator, Share Price Rises

Pro Medicus (ASX: PME) made an announcement this morning about it showcasing its Visage AI Accelerator, which sent the share price higher.

Pro Medicus Limited (ASX:PME) is a Melbourne-based software owner and developer, licensing products to large US hospitals and Australian radiology clinics. The company has offices in Richmond, Victoria, Berlin, Germany and in the United States.

Pro Medicus’ US Announcement

Pro Medicus said that its US subsidiary Visage Imaging Inc will be showcasing the Visage AI Accelerator solution and the new Visage developed breast density classification algorithm at the Radiological Society of North America (RSNA) conference at the start of December 2019.

Visage AI Accelerator is described by Pro Medicus as a multi-faceted, end to end solution translating AI ‘from research to bedside’.

The technology it will be showcasing today includes the Visage 7 AI research server as well as specialised data creation and annotation tools including the new semantic annotation capability to bridge the entire spectrum from research to diagnostic use via a single platform.

A key to this accelerator solution is an open application program interface (API) that enables integration of both Visage and third-party developed algorithms into the Visage 7 product.

Pro Medicus CEO Dr Sam Hupert explained that radiologists don’t want separate systems when it comes to AI, which is why the company developed an open API so that customers could choose the algorithms that best suit their needs whilst being integrated into the Visage 7 Enterprise Imaging Platform.

Dr Hupert said: “We have a pilot implementation of our new Visage 7 semantic annotations ongoing at Partners HealthCare Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (CWH) Center for Clinical Data Science, where the framework is being defined and tested in the radiology workflow. 

We are also excited to be working closely with the American College of Radiology (ACR) Data Science Institute to integrate Visage 7 and semantic annotations with the ACR AI-LAB, an initiative that offers radiologists tools designed to help them learn the basics of AI and participate directly in the creation, validation and use of health care AI.”

The company will also be highlighting its new breast density classification algorithm (WIP) developed in collaboration with Yale New Haven Health.

[ls_content_block id=”18457″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content